- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03843840
Dual Wavelength OCT
April 4, 2022 updated by: Moorfields Eye Hospital NHS Foundation Trust
Combined Coaxial Optical Coherence Tomography System to Image the Retina and Choroidal Structures and Estimate Tissue Reflectivity in Healthy and Diseased Retinas
The purpose of this research is the evaluation of a combined coaxial optical coherence tomography (OCT) system to image retina/choroid and to evaluate if post processing of the data can give us insights into property of the tissue imaged.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Histology studies have shown that many disorders of the retina and choroid such as age-related macular degeneration is associated with a build up abnormal deposits, in the retina or subretinal space.
Being able to detect subtle changes in retina and choroidal structure is crucial for better understanding and monitoring of this potentially blinding condition.
This study aims to commercially available Spectralis® OCT-system with a central wavelength of 880nm explore the ability of a confocal scanning laser ophthalmoscope (cSLO) for OCT imaging utilising a modified by the addition of a longer wavelength OCT (1075nm , a wavelength deployed on other commercially available OCT scanners).
Other commercially available OCT scanners used longer wavelengths to allow deeper penetration and enhanced visualisation of subretinal tissue but less inner retinal detail.
Combing both wavelengths could have the advantage of allowing optimum viualisation of inner and subretinal structures.
The ability of the systems to acquire repeatable and good quality images of retinal and choroidal structural detail at matching location and compare the results from the two instruments will be evaluated.
In addition processing of the images reflectivity with two different wavelength should give us insight into the nature of any abnormal material.
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, EC1V 2PD
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
People with diseased retina
Description
Inclusion Criteria:
- Age>18
- Ability to consent
- Abnormal reflectivity detected in at least one eye in the retina or choroid on OCT testing undertaken as part of routine
- clinical care
Exclusion Criteria:
- Media opacities on conventional OCT testing taken on the day of the study visit, that prevents adequate visualisation of
- the retina and/or choroidal substructures in the opinion of the investigator
- Inability to undertake to undertake two additional OCT scans on each eye in addition to their conventional OCT.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Diseased Retina
|
Taking images of the retina with two wavelengths
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Test retest reliability
Time Frame: 14 months
|
Comparison of device test retest variability with those of standard OCT for measurement of tissue reflectivity.
|
14 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2019
Primary Completion (Actual)
November 30, 2019
Study Completion (Actual)
October 21, 2020
Study Registration Dates
First Submitted
May 31, 2018
First Submitted That Met QC Criteria
February 15, 2019
First Posted (Actual)
February 18, 2019
Study Record Updates
Last Update Posted (Actual)
April 12, 2022
Last Update Submitted That Met QC Criteria
April 4, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TUFA1040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Degeneration
-
Seoul National University Bundang HospitalUnknownAge-Related Macular Degeneration | Retinal DrusenKorea, Republic of
-
University of LuebeckCompletedAge-Related Macular Degeneration | Retinal FunctionGermany
-
Stanford UniversityBascom Palmer Eye InstituteCompletedMacular Degeneration | Retinal DrusenUnited States
-
Guardion Health Sciences, Inc.Western University of Health Sciences; Eye Clinic of AustinCompletedMacular Degeneration | Age-related Macular Degeneration | Retinal DrusenUnited States
-
Benha UniversityRecruitingMacula Lutea DegenerationUnited Arab Emirates
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationJapan
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationItaly
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance
-
Sorlandet Hospital HFActive, not recruitingWet Macular DegenerationNorway
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance
Clinical Trials on Combined Coaxial Optical Coherence Tomography
-
University Hospital, Basel, SwitzerlandCompleted
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedCerebral AneurysmUnited States
-
Samsung Medical CenterCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedTransitional Cell Carcinoma of Urinary TractNetherlands
-
Khon Kaen UniversityRecruitingRetinal Vascular | Twin Pregnancy, Antepartum Condition or Complication | Choroidal EffusionThailand
-
Kasr El Aini HospitalCompletedTractional Retinal Detachment | Diabetic Vitreous HemorrhageEgypt
-
Khon Kaen UniversityNot yet recruiting
-
Medical University of ViennaRecruitingMultiple Sclerosis, Relapsing-Remitting | Optic NeuritisAustria
-
China National Center for Cardiovascular DiseasesBeijing Tongren HospitalNot yet recruiting
-
Khon Kaen UniversityNot yet recruitingPregnancy Related | High Myopia